salt-licker

6 ms·

1.
Genesis Therapeutics announces $200M Series B co-led by Andreessen Horowitz(genesistherapeutics.ai)
7 points by salt-licker 3y ago|0 comments
2.
by salt-licker 4y ago
AirPods Pro noise cancellation almost definitely gave me temporary tinnitus after a few months of usage even though I never listened to music that loud. Switched to regular AirPods two years ago and the tinnitus entirely went away.
3.
by salt-licker 4y ago
Genesis Therapeutics | Burlingame, CA | Remote or Onsite | Full-time or Interns | https://www.genesistherapeutics.ai We’re a hybrid AI + biotech start-up, developing novel deep learning and molecular simulation techniques to pre
4.
by salt-licker 4y ago
Genesis Therapeutics | Burlingame, CA | Remote or Onsite | Full-time or Interns | https://www.genesistherapeutics.ai We’re a hybrid AI + biotech start-up, developing novel deep learning and molecular simulation techniques to pre
5.
by salt-licker 4y ago
Genesis Therapeutics | Burlingame, CA | Remote or Onsite | Full-time or Interns | https://www.genesistherapeutics.ai We’re a hybrid AI + biotech start-up, developing novel deep learning and molecular simulation techniques to pre
6.
by salt-licker 4y ago
Genesis Therapeutics | Burlingame, CA | Remote or Onsite | Full-time or Interns | https://www.genesistherapeutics.ai We’re a hybrid AI + biotech start-up, developing novel deep learning and molecular simulation techniques to pre
7.
by salt-licker 4y ago
Genesis Therapeutics | Burlingame, CA | Remote or Onsite | Full-time | https://www.genesistherapeutics.ai We’re a hybrid AI + biotech start-up, developing novel deep learning and molecular simulation techniques to predict molecu
8.
by salt-licker 4y ago
Genesis Therapeutics | Burlingame, CA | Remote or Onsite | Full-time | https://www.genesistherapeutics.ai We’re a hybrid AI + biotech start-up, developing novel deep learning and molecular simulation techniques to predict molecu
9.
by salt-licker 4y ago
Genesis Therapeutics | Burlingame, CA | Remote or Onsite | Full-time | https://www.genesistherapeutics.ai We’re a hybrid AI + biotech start-up, developing novel deep learning and molecular simulation techniques to predict molecu
10.
by salt-licker 4y ago
Genesis Therapeutics | Burlingame, CA | Remote or Onsite | Full-time | https://www.genesistherapeutics.ai We’re a hybrid AI + biotech start-up, developing novel deep learning and molecular simulation techniques to predict molecu
11.
by salt-licker 4y ago
Genesis Therapeutics | Burlingame, CA | Onsite (Flexible WFH) | Full-time | https://www.genesistherapeutics.ai We’re a hybrid AI + biotech start-up, developing novel deep learning and molecular simulation techniques to predict m
12.
by salt-licker 5y ago
Genesis Therapeutics | Burlingame, CA | Onsite (Flexible WFH) | Full-time | https://www.genesistherapeutics.ai We’re a hybrid AI + biotech start-up, developing novel deep learning and molecular simulation techniques to predict m
13.
by salt-licker 5y ago
Genesis Therapeutics | Burlingame, CA | Onsite (Flexible WFH) | Full-time | https://www.genesistherapeutics.ai We’re a hybrid AI + biotech start-up, developing novel deep learning and molecular simulation techniques to predict m
14.
by salt-licker 5y ago
Genesis Therapeutics | Burlingame, CA | Onsite (Flexible WFH) | Full-time | https://www.genesistherapeutics.ai We’re a hybrid AI + biotech start-up, developing novel deep learning and molecular simulation techniques to predict m
15.
by salt-licker 5y ago
Genesis Therapeutics | Burlingame, CA | Onsite (Flexible WFH) | Full-time | https://www.genesistherapeutics.ai We’re a hybrid AI + biotech start-up, developing novel deep learning and molecular simulation techniques to predict m
16.
by salt-licker 5y ago
Which contribute to a chip shortage making cars more expensive, seemingly pure financial instruments directly causing inflation for everyday people, there is no escape
17.
by salt-licker 5y ago
I often wonder if being too close to the experimental results and current techniques blinds some people from seeing the bigger picture. Gwern certainly seems good at analyzing large-scale trends in AI research, perhaps broad high-level know
18.
by salt-licker 5y ago
Do you consider gwern not to be an AI expert? I think this is a reasonably technical explanation of how we may not be as far away from AGI as some choose to believe: https://www.gwern.net/Scaling-hypothesis
19.
by salt-licker 6y ago
Sounds like the mission of Day Zero Diagnostics (dayzerodiagnostics.com). Are you working with them?
20.
by salt-licker 6y ago
Genesis Therapeutics | Burlingame, CA | Onsite (Flexible WFH) | Full-time | https://www.genesistherapeutics.ai We’re a hybrid AI + biotech start-up, developing novel graph neural networks to predict molecular properties and usin
21.
by salt-licker 6y ago
Julia’s type system is not particularly user-friendly. For example, it has both a “String” and a “SubString” type which cannot always be interchanged. Their language design seem to be much more concerned with execution speed than programmer
22.
by salt-licker 6y ago
Genesis Therapeutics | Burlingame, CA | Onsite (Flexible WFH) | Full-time | https://www.genesistherapeutics.ai We’re a hybrid AI + biotech start-up, developing novel neural networks to predict molecular properties and using them
23.
by salt-licker 6y ago
This is an excellent point. 3D printing will likely never replace injection molding for plastic parts above a volume of a few thousand. This is well known in the industry but largely unexamined by the media. High-strength 3D printing howeve
24.
Genesis Therapeutics raises $52M Series A for AI-based drug discovery(techcrunch.com)
4 points by salt-licker 6y ago|1 comments
25.
by salt-licker 6y ago
Genesis Therapeutics | Burlingame, CA | Onsite (Flexible WFH) | Full-time | https://www.genesistherapeutics.ai We’re a hybrid AI + biotech start-up, developing novel neural networks to predict molecular properties and using them
26.
by salt-licker 6y ago
Genesis Therapeutics | Burlingame, CA | Onsite (Flexible WFH) | Full-time | https://www.genesistherapeutics.ai We’re a hybrid AI + biotech start-up, developing novel neural networks to predict molecular properties and using them
27.
by salt-licker 6y ago
This article lacks nuance around the tradeoffs inherent in shipping complex software at maximum velocity. Much more useful is evaluating the long-term impact of specific instances of technical debt, particularly “contagion”: https:/&#
28.
by salt-licker 6y ago
How is this differentiated from hypem.com?
29.
by salt-licker 6y ago
Quality-Adjusted Life Years is a common measure of disease burden. Also, I think a parent who has lost a child would have something to say to you about the difference in emotional impact
30.
by salt-licker 6y ago
Well-written post, but the suggested solution of HTS on mice is nonsensical. First of all, we’ve cured cancer in mice many times but it’s obviously still unsolved in humans. Secondly, you’re constraining yourself to synthesized chemical spa

More ›